DNA-tailored diet could help manage blood glucose and reduce risk of type 2 diabetes progression

Gilead is ex­pand­ing and re­new­ing an IT con­tract with Cog­nizant that is now worth up to $800 mil­lion over five years. Cog­nizant said Mon­day that

Bil­lion­aire Alvotech CEO Róbert Wess­man told in­vestors on Thurs­day that the com­pa­ny has re­sub­mit­ted its Hu­mi­ra in­ter­change­able biosim­i­lar ap­pli­ca­tion to the FDA af­ter re­ceiv­ing a